OppenheimerFunds Inc. boosted its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 21.8% during the first quarter, according to its most recent filing with the SEC. The firm owned 16,130 shares of the medical instruments supplier’s stock after buying an additional 2,883 shares during the period. OppenheimerFunds Inc.’s holdings in AngioDynamics were worth $280,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of the company. Texas Permanent School Fund boosted its stake in shares of AngioDynamics by 0.6% in the first quarter. Texas Permanent School Fund now owns 23,129 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 145 shares during the period. Municipal Employees Retirement System of Michigan boosted its stake in shares of AngioDynamics by 3.0% in the first quarter. Municipal Employees Retirement System of Michigan now owns 7,200 shares of the medical instruments supplier’s stock valued at $125,000 after buying an additional 210 shares during the period. Louisiana State Employees Retirement System boosted its stake in shares of AngioDynamics by 2.4% in the first quarter. Louisiana State Employees Retirement System now owns 13,000 shares of the medical instruments supplier’s stock valued at $226,000 after buying an additional 300 shares during the period. Arizona State Retirement System boosted its stake in shares of AngioDynamics by 2.5% in the first quarter. Arizona State Retirement System now owns 16,596 shares of the medical instruments supplier’s stock valued at $288,000 after buying an additional 400 shares during the period. Finally, New York State Teachers Retirement System boosted its stake in shares of AngioDynamics by 3.4% in the fourth quarter. New York State Teachers Retirement System now owns 15,086 shares of the medical instruments supplier’s stock valued at $255,000 after buying an additional 500 shares during the period. 89.19% of the stock is currently owned by hedge funds and other institutional investors.
Shares of AngioDynamics, Inc. (ANGO) traded up 0.29% during midday trading on Friday, reaching $17.10. The company’s stock had a trading volume of 459,833 shares. AngioDynamics, Inc. has a 52 week low of $14.80 and a 52 week high of $18.18. The stock has a market capitalization of $625.52 million, a PE ratio of 124.82 and a beta of 1.15. The company has a 50 day moving average price of $16.26 and a 200-day moving average price of $16.18.
AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Tuesday, July 18th. The medical instruments supplier reported $0.19 EPS for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.03. The company had revenue of $86.90 million during the quarter, compared to the consensus estimate of $90.72 million. AngioDynamics had a net margin of 2.00% and a return on equity of 5.19%. AngioDynamics’s quarterly revenue was down 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.19 EPS. On average, equities research analysts expect that AngioDynamics, Inc. will post $0.67 EPS for the current year.
TRADEMARK VIOLATION WARNING: This news story was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://stocknewstimes.com/2017/08/18/oppenheimerfunds-inc-raises-position-in-angiodynamics-inc-nasdaqango-updated-updated-updated.html.
Several equities research analysts have recently issued reports on the company. Zacks Investment Research raised AngioDynamics from a “sell” rating to a “hold” rating in a report on Monday. Cantor Fitzgerald lifted their target price on AngioDynamics from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Tuesday, July 4th. Barclays PLC reduced their target price on AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 19th. Canaccord Genuity reaffirmed a “hold” rating and issued a $17.00 target price on shares of AngioDynamics in a report on Tuesday, July 18th. Finally, BidaskClub cut AngioDynamics from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $18.50.
In other AngioDynamics news, CEO James C. Clemmer acquired 20,000 shares of the business’s stock in a transaction on Thursday, July 20th. The stock was bought at an average price of $15.64 per share, for a total transaction of $312,800.00. Following the acquisition, the chief executive officer now owns 86,683 shares in the company, valued at $1,355,722.12. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO James C. Clemmer acquired 5,000 shares of the business’s stock in a transaction on Friday, July 21st. The stock was acquired at an average price of $15.79 per share, with a total value of $78,950.00. Following the acquisition, the chief executive officer now owns 86,683 shares in the company, valued at approximately $1,368,724.57. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 25,316 shares of company stock valued at $396,806. 1.88% of the stock is owned by insiders.
About AngioDynamics
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
